Alliance A051701 (Lymphoma) - Clinical Trial

We are doing this study to see how an experimental drug called venetoclax works in your body and against your cancer. We want to know if the addition of this drug to standard chemotherapy can improve treatment for people with double-hit or double expressing lymphoma. These lymphoma types are aggressive (fast-growing) B-cell lymphomas.

MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Adults who have double-hit or double expressing lymphoma.

If you choose to join the study, you will:
- Be randomly assigned (like the flip of a coin) to 1 of 2 groups
-- One group will receive standard chemotherapy (R-CHOP or EPOCH-R) for up to 18 weeks
-- The other group will receive standard chemotherapy plus the study drug venetoclax for up to 18 weeks

R-CHOP chemotherapy uses the following drugs:
- Rituximab (R)
- Cyclophosphamide (C)
- Doxorubicin (H)
- Vincristine (O)
- Prednisone (P)

EPOCH-R chemotherapy uses the following drugs:
- Etoposide (E)
- Prednisone (P)
- Vincristine (O)
- Cyclophosphamide (C)
- Doxorubicin (H)
- Rituximab (R)

When your treatment is finished, you will:
- Have follow-up visits every 3 months for the first 2 years after treatment
- Have follow-up visits every 6 months for the 3rd, 4th, and 5th years after treatment
- Have follow-up phone calls or visits every 6 months for another 5 years once it has been 5 years after treatment